Hermes Vector

Health

CG Oncology bladder cancer therapy cuts recurrence risk by 68% in Phase 3 trial

CG Oncology says cretostimogene grenadenorepvec reduced recurrence risk by 68% in the 367-patient PIVOT-006 trial, with two FDA filings planned for 2027.

By Hermes Vector

Also in: Español · Português · Français

Checked against 4 sourcesfinance.biggo.comapp.dealroom.comlq.aistocktitan.net
Illustration for: CG Oncology bladder cancer therapy cuts recurrence risk by 68% in Phase 3 trial

In brief

  • Cretostimogene reduced recurrence risk by 68% in the 367-patient Phase 3 PIVOT-006 trial, with a hazard ratio of 0.32.
  • No Grade 3 or higher treatment-related adverse events or treatment-related discontinuations were reported.
  • CG Oncology plans a second FDA filing in Q2 2027 and an expanded BCG-unresponsive filing before the end of March 2027.
  • About 50,000 U.S. patients in this population have no FDA-approved adjuvant treatment option, according to the company.

CG Oncology bladder cancer therapy cuts recurrence risk by 68% in Phase 3 trial

CG Oncology, Inc. reported positive topline results from PIVOT-006, its Phase 3 registrational trial of cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC) following complete tumor resection. The company said the therapy reduced the risk of tumor recurrence by 68% versus the control arm, with a hazard ratio of 0.32 over a median 17 months of follow-up as of October 26, 2026.

Trial results and safety

PIVOT-006 enrolled 367 patients at about 90 sites in the United States and Canada. The study compared adjuvant intravesical cretostimogene grenadenorepvec with surveillance after complete tumor resection. The company said the trial met its primary endpoint, with a 95% confidence interval of 0.23 to 0.45 and p<0.0001.

CG Oncology reported no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. The company said safety results were consistent with those reported in previous studies.

Regulatory plans

The company plans a second FDA application in intermediate-risk, high-grade Ta non-muscle invasive bladder cancer in the second quarter of 2027. It also plans to widen its original submission in BCG-unresponsive disease beyond patients with carcinoma in situ, with or without papillary tumors, to include those with high-grade papillary-only disease. CG Oncology said the change would produce a label reflecting the full range of patients whose cancer does not respond to Bacillus Calmette-Guerin, the standard first-line therapy.

To fold in the additional data, the company pushed completion of that expanded submission to before the end of March 2027. It said all manufacturing activities needed to support both filings are finished.

Company statements

"The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase 3 trial in intermediate-risk and HG Ta NMIBC," said Arthur Kuan, Chairman, President and Chief Executive Officer of CG Oncology.

"Today's results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum," Chief Medical Officer Vijay Kasturi said in a release.

Why it matters

Roughly 50,000 U.S. patients in the PIVOT-006 population have no approved adjuvant option, according to the company. Cretostimogene has previously received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC, and its development programme covers more than 700 patients with NMIBC. PIVOT-006 data will be presented as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on 2 December 2026.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

What were the results of the PIVOT-006 Phase 3 trial for CG Oncology's cretostimogene grenadenorepvec?
The therapy reduced the risk of tumor recurrence by 68% versus the control arm, with a hazard ratio of 0.32 over a median 17 months of follow-up as of October 26, 2026.
How many patients were enrolled in the PIVOT-006 trial and where were they located?
PIVOT-006 enrolled 367 patients at about 90 sites in the United States and Canada.
When will the data from the PIVOT-006 trial be presented?
PIVOT-006 data will be presented as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on 2 December 2026.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.